An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
Status:
Terminated
Trial end date:
2019-05-31
Target enrollment:
Participant gender:
Summary
In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks
(Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet
eligibility criteria in order to evaluate safety in participants on long-term crenezumab
treatment and to investigate the effect of crenezumab on the underlying disease process and
disease course as an exploratory efficacy objective.